TAK-700 – No competitive edge against Zytiga Generics; while in early setting competition is also heating up! In the recent past, treatment paradigm of metastatic prostate cancer (mPC) has witnessed
Merck -Suvorexant delayed but no additional studies required is a sigh of relief
Date:
2015-07
MORE PUBLICATIONS
Merck -Suvorexant delayed but no additional studies required is a sigh of relief
US$ 90 2015-07 Pages: 1Categories
- Automotive
- Bearings
- Business Services
- Chemicals and Materials
- Coatings
- Company Profiles
- Consumer Goods
- Defense
- Electronics
- Energy
- Financial Services
- Food & Beverages
- Manufacturing & Construction
- Medical Devices
- Pharmaceuticals and Healthcare
- Public Sector
- Resins
- Technology
- Telecommunications and Wireless
- Vacuum Products
Popular Articles
- Mayo Clinic – Strategic SWOT Analysis Review
- Berjaya Corporation Berhad (BJCORP) – Financial and Strategic SWOT Analysis Review
- Global In Vitro Diagnostics (IVD) Market Analysis By Technology
- Basware is the world’s Largest Integrated Provider of Electronic Invoices Services
- Global Needle-Free Injection Device Market Worth $ 935 Million by 2019
- Global Disposable Diapers Market Analysis
- Chinese Machine Vision Market Reached 1.65 Billion RMB in 2014
- Global Polyimide Varnish Market Worth $ 6.1 Billion by 2021
- Global Energy Drink Market Will Grow At A CAGR Of Approximately 8.6%
- Sprint Corporation (S) – Financial and Strategic SWOT Analysis Review
